The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
Cyclin-dependent protein kinases 4/6 inhibitor:ribociclib
Author(s): 
Pages: 1162-1166
Year: Issue:  9
Journal: World Phytomedicines

Keyword:  cyclin-dependent protein kinases 4/6breast cancermelanomanon-small cell lung cancer;
Abstract: The incidence of breast cancer is increasing year by year, and has become a major public health problem in the world. Cycle dependent protein kinase (CDK) 4/6 inhibitor can block cell cycle in G1 phase, which can inhibit tumor growth. Ribociclib is a highly specific protein kinases 4/6 inhibitor, which can inhibit D1/CDK4 and D3/CDK6 cell cycle, and has potential antitumor activity. The results of clinical trials indicate that ribociclib has clinical efficacy in treatment of breast cancer, melanoma, non-small cell lung cancer, teratoma, liposarcoma, and glioblastoma.
Related Articles
No related articles found